EHA 2019: Intervention for AML patients with MRD can result in improved survival

Christopher Hourigan | EHA 2019 | Juni 17, 2019

Föreläsare: Christopher Hourigan

Patients with acute myeloid leukemia (AML) are at risk of relapse after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable residual disease (MRD) status prior to alloHCT has been shown to be prognostic. It is currently unknown if modulating the intensity of the alloHCT conditioning regimen in AML patients testing positive for MRD can prevent relapse and improve survival rates. 

Click and hear Christopher Hourigan give the answer.